Opdivo Plus Chemotherapy as Adjuvant Therapy in Gastric Cancer: ATTRACTION-5 Trial

At the ASCO 2023 Annual Meeting, Dr. Masanori Terashima from Shizuoka Cancer Center presented the results of the ATTRACTION-5 Phase 3 clinical trial. This study investigated the efficacy and safety of adding Opdivo (Nivolumab) to postoperative adjuvant chemotherapy for patients with Pathological Stage III gastric or gastroesophageal junction (GEJ) cancer.

Study Design: ATTRACTION-5 Trial

ATTRACTION-5 was a multicenter, randomized, double-blind trial. Patients who had undergone radical surgery for Stage III gastric or GEJ cancer and were eligible for adjuvant chemotherapy were randomized to receive:

1. Opdivo + Chemotherapy
2. Placebo + Chemotherapy

The primary endpoint was relapse-free survival (RFS).

Key Results (Median Follow-up 36 Months)

The trial did not meet its primary endpoint of demonstrating a statistically significant improvement in RFS:

• 3-Year RFS Rate: 68.4% for the Opdivo + Chemotherapy group vs. 65.3% for the placebo group.
• The difference between the two groups was not considered statistically significant at the time of analysis.

Safety Profile

• Grade 3 or higher Adverse Events: 54.4% in the Opdivo group vs. 46.8% in the placebo group.
• Serious Adverse Events: 25.3% in the Opdivo group vs. 10.7% in the placebo group.
• Discontinuation Rate due to Side Effects: 9.2% in the Opdivo group vs. 3.5% in the placebo group.

Conclusion

Dr. Terashima and the research team concluded that adding Opdivo to postoperative adjuvant chemotherapy did not significantly improve relapse-free survival in patients with Pathological Stage III gastric or GEJ cancer compared to chemotherapy alone.

Source: ASCO 2023 - ATTRACTION-5 Abstract

#GastricCancer #GEJCancer #Opdivo #Nivolumab #ATTRACTION5 #AdjuvantTherapy #CancerResearch

Figure 1

Figure 2

Figure 3

Figure 4